E U R O P E A N U R O L O G Y X X X ( 2 0 1 8 ) X X X -X X X a v a i l a b l e a t w w w . s c i e n c e d i r e c t . c o m j o u r n a l h o m e p a g e : w w w . e u r o p e a n u r o l o g y . c o m
There are currently several approved life-prolonging therapies for the treatment of metastatic castrationresistant prostate cancer (mCRPC), including androgen receptor (AR)-directed drugs and taxanes. Plasma DNA analysis from mCRPC patients has suggested potential clinical applicability with an association between plasma AR aberrations and worse outcome with AR-directed drugs [1] [2] [3] [4] [5] . To date, detection of AR splice variants has been shown to have potential utility for the selection of taxane versus AR-targeted therapy for patients with mCRPC [6, 7] . However, the relevance of plasma AR status in the context of taxanes is unknown. We here aimed to evaluate the association of plasma AR status with outcomes in mCRPC patients treated with docetaxel. Additionally, we aimed to perform an exploratory analysis to compare the difference in outcome by plasma AR status for patients treated either with first-line docetaxel or AR-directed therapy.
Plasma samples were collected, with the primary aim of biomarker evaluation, from mCRPC patients, treated with standard-dose intravenous docetaxel 75 mg/m 2 every 3 wk with prednisone 5 mg twice daily for a maximum of 10 cycles for mCRPC [8] , between May 2011 and January 2017 in 20 institutions. For the exploratory analysis, we included data on patients from our previous publication [5] who received abiraterone/enzalutamide prior to chemotherapy at the development of mCRPC, with updated clinical follow-up with a cut-off date of December 2017. All patients provided signed consent to an institutional review boardapproved protocol before sample collection. Selection criteria, procedures, and the AR copy number (CN) droplet digital polymerase chain reaction assay are described in the Supplementary material. We set out to determine AR status in plasma collected from 166 docetaxel-treated mCRPC patients prior to first-or second-line mCRPC therapy (Fig. 1A) , but we had sample failure in three cases. We detected plasma AR gain in 50 patients (31%; 28% AR gain prior to first-line and 37% prior to second-line therapy). The median number of docetaxel cycles was the same in AR-normal and AR-gained patients (median 8, interquartile range 6-10). The median follow-up period of alive patients was 24 mo. As 98% of the deaths were prostate cancer related, only overall survival (OS), and not cancer-specific survival, was analyzed. The median OS was 14 mo (95% confidence interval [CI] 12-23) for AR-gained patients and 22 mo (95% CI 20-29) for ARnormal patients. Median progression-free survival (PFS) was 7 mo (95% CI 5-8) in AR-gained patients and 7 mo (95% CI 6-8) in AR-normal patients. OS was significantly shorter in AR-gained versus AR-normal patients (hazard ratio [HR] = 1.61, 95% CI 1.08-2.39, p = 0.02), but no significant difference was observed for PFS (HR = 1.04, 95% CI 0.74-1.46,p = 0.8) or prostate-specific antigen (PSA) decline 50% (odds ratio = 1.14, 95% CI 0.65-1.99, p = 0.7; Fig. 1B-D) .
Next, we selected the 115 patients treated with docetaxel as first-line therapy and in an exploratory, analysis compared them with 73 previously described patients treated with first-line abiraterone/enzalutamide (Fig. 1A ) [5] . A comparison of clinicopathological characteristics between patients receiving either docetaxel or abiraterone/ enzalutamide as first-line therapy showed significant differences in age, site of metastases, PSA, lactate dehydrogenase (LDH), hemoglobin, alkaline phosphatase, and plasma AR status (Supplementary Table 1 ). When comparing AR-normal with AR-gained patients in each treatment group, serum LDH and PSA were significantly higher in ARgained patients treated with abiraterone/enzalutamide and serum alkaline phosphatase was significantly higher in plasma AR-gained patients treated with docetaxel (Supplementary Table 2 ).
The interaction of docetaxel or abiraterone/enzalutamide therapy and AR status was investigated using a multivariable Cox proportional hazard model, which showed a significant treatment interaction with AR status for both OS (HR = 0.16, 95% CI 0.06-0.46, p < 0.001) and PFS (HR = 0.31, 95% CI 0.12-0.80, p = 0.02; Supplementary Table 3 ). The median follow-up period for alive patients of the abiraterone/enzalutamide cohort was 32 mo.
The estimated median OS and PFS as a function of treatment and AR CN status are depicted in Figures 2A and naïve, abiraterone/enzalutamide-treated patients, with data from 115 first-line docetaxel patients. In an exploratory analysis of mCRPC patients receiving first-line therapies, a significant interaction was observed between plasma AR and docetaxel versus abiraterone/enzalutamide for OS (HR = 0.16, 95% CI = 0.06-0.46, p < 0.001) and PFS (HR = 0.31, 95% CI = 0.12-0.80, p = 0.02). Specifically, we reported a significant difference for OS favoring abiraterone/enzalutamide for AR-normal patients (HR = 1.93, 95% CI = 1.19-3.12, p = 0.008) and a suggestion favoring docetaxel for AR-gained patients (HR = 0.53, 95% CI = 0.24-1.16, p = 0.11). These data suggest that AR-normal patients should receive abiraterone/enzalutamide and AR-gained could benefit from docetaxel. This treatment selection merits prospective evaluation in a randomized trial. Patient summary: We investigated whether plasma androgen receptor (AR) predicted outcome in metastatic castration-resistant prostate cancer (mCRPC) patients treated with docetaxel, and we performed an exploratory analysis in patients treated with docetaxel or AR-directed drugs as first-line mCRPC therapy. We showed that plasma AR normal favored hormonal treatment, whilst plasma AR-gained patients may have had a longer response to docetaxel, suggesting that plasma AR status could be a useful treatment selection biomarker.2B, respectively. The HRs for OS (Fig. 2C) and PFS (Fig. 2D ) estimated from the Cox proportional hazard regression analyses suggested that AR-normal patients treated with abiraterone/enzalutamide had a significantly lower risk of death (HR = 1.93, 95% CI 1.19-3.12, p = 0.008) and progressive disease (HR = 2.60, 95% CI 1.75-3.86, p < 0.001) when compared with those treated with docetaxel, and in ARgained patients there was a suggestion toward a lower risk of death (HR = 0.53, 95% CI 0.24-1.16, p = 0.11; Fig. 2C ) and progressive disease (HR = 0.82, 95% CI 0.40-1.69, p = 0.6; Fig. 2D ) with docetaxel compared with abiraterone/ enzalutamide therapy. In multivariable analysis of first-line treatment patients, including treatment type, plasma AR status, and other pretreatment baseline features previously shown to be clinically relevant [5] , we observed that plasma AR gain was independently associated with worse OS (HR = 6.55, 95% CI 2.74-15.68, p < 0.001) and PFS (HR = 3.24, 95% CI 1.47-7.14, p = 0.004; Supplementary Table 3) .
Metastatic CRPC patients can be treated with docetaxel or AR-targeting therapies as first-line therapy. We and others have reported that detection of circulating AR aberrations is associated with worse outcome on abiraterone/enzalutamide [2] [3] [4] [5] . In this study, we report that plasma AR gain in docetaxel-treated patients was associated with significantly shorter OS. This emphasizes the urgent clinical need of alternative treatments for AR-gained patients [9] . Retrospective studies have suggested that AR-V7 expression in mCRPC men can be considered a treatment-specific biomarker associated with superior survival for taxane therapy compared with AR therapies [6, 7] . Here, we explored whether plasma AR gain status is associated with resistance to taxanes in an abiraterone/ enzalutamide-naïve population and, to avoid the influence of possible cross-resistance events on the interpretation of survival data, we compared it with the effect seen in taxanenaïve abiraterone/enzalutamide-treated patients [10] . The absence of a difference in outcome by AR status in treatment-naïve docetaxel-treated patients introduces the hypothesis that AR-gained patients would derive greater benefit from treatment with taxanes in preference to abiraterone/enzalutamide. However, we recognize some limitations of our study, including the significantly different durations of median follow-up of alive patients between the docetaxel and the abiraterone/enzalutamide cohort (24 vs 32 mo, with overall follow-up of 24 mo); the relatively modest sample size of the cohorts, especially of AR-gained patients treated with abiraterone/enzalutamide (n = 10); and the retrospective, nonrandomized design. The majority of patients were treated with taxanes in centers when abiraterone or enzalutamide were not widely available prior to chemotherapy. Nonetheless, there could be a bias due to patient selection, given the different toxicity profiles of taxanes compared with AR-targeting drugs. Additionally, detection of an AR-gained clone may be more likely at higher circulating tumor fraction that in itself is prognostic; this could bias the ability to ascertain the predictive value of plasma AR with AR-targeting drugs but would not change the interpretation of the absence of difference in our treatment-naive taxane-treated cohort. Lastly, we only considered AR gain, but other concurrently assessed AR aberrations (somatic point mutations or splice variants) could provide additional or overlapping information. Our findings suggest that AR gain detected in plasma is associated with resistance to abiraterone/enzalutamide but not with taxanes when used in the first-line setting. In conclusion, prospective randomized trials are warranted to validate the utility of plasma AR status for treatment selection in mCRPC patients.
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